Jin, G.; Zheng, K.; Liu, S.; Yi, H.; Wei, W.; Xu, C.; Xiang, X.; Kang, Y.
In Vivo PK-PD and Drug–Drug Interaction Study of Dorzagliatin for the Management of PI3Kα Inhibitor-Induced Hyperglycemia. Pharmaceuticals 2025, 18, 927.
https://doi.org/10.3390/ph18060927
AMA Style
Jin G, Zheng K, Liu S, Yi H, Wei W, Xu C, Xiang X, Kang Y.
In Vivo PK-PD and Drug–Drug Interaction Study of Dorzagliatin for the Management of PI3Kα Inhibitor-Induced Hyperglycemia. Pharmaceuticals. 2025; 18(6):927.
https://doi.org/10.3390/ph18060927
Chicago/Turabian Style
Jin, Guanqin, Kewei Zheng, Shihuang Liu, Huan Yi, Wei Wei, Congjian Xu, Xiaoqiang Xiang, and Yu Kang.
2025. "In Vivo PK-PD and Drug–Drug Interaction Study of Dorzagliatin for the Management of PI3Kα Inhibitor-Induced Hyperglycemia" Pharmaceuticals 18, no. 6: 927.
https://doi.org/10.3390/ph18060927
APA Style
Jin, G., Zheng, K., Liu, S., Yi, H., Wei, W., Xu, C., Xiang, X., & Kang, Y.
(2025). In Vivo PK-PD and Drug–Drug Interaction Study of Dorzagliatin for the Management of PI3Kα Inhibitor-Induced Hyperglycemia. Pharmaceuticals, 18(6), 927.
https://doi.org/10.3390/ph18060927
